Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma.

ABSTRACT:

Background

Existing economic model frameworks may not adequately capture the atypical treatment response patterns in immuno-oncology (I-O) compared with conventional therapies and thus may fail to represent the full clinical value associated with disease dynamics and improved survival.

Objective

A cost-effectiveness analysis (CEA) of the I-O Regimen (nivolumab/ipilimumab) versus ipilimumab alone in advanced melanoma was carried out by applying a 5-state partitioned survival model (PSM) as a case study, to explore the I-O treatment response and clinical outcomes. The findings were compared with those of a conventional 3-state PSM.

Materials and methods

The case study extends the conventional 3-state PSM, by separating the pre-progression state into non-responders and r

SUBMITTER: Gibson EJ 

PROVIDER: S-EPMC7220542 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature